Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Common symptoms of a liver tumor include ... Other types of liver cancer include hepatocellular carcinoma (a tumor grows on ...

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few—in this case, children, adolescents, and young adults. Because its symptoms can vary from person to ...